Calcitonin - PPL Therapeutics

Drug Profile

Calcitonin - PPL Therapeutics

Alternative Names: Salcatonin - PPL Therapeutics

Latest Information Update: 09 Feb 2000

Price : $50

At a glance

  • Originator PPL Therapeutics PLC
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Postmenopausal osteoporosis

Most Recent Events

  • 09 Feb 2000 Suspended-Preclinical for Postmenopausal osteoporosis in United Kingdom (Unknown route)
  • 12 Nov 1998 New profile
  • 12 Nov 1998 Preclinical development for Postmenopausal osteoporosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top